moneyheap
ACLS · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Axcelis Technologies Inc (ACLS) stock moving?
Axcelis beat Q3 expectations on Nov 5, with revenue of $237.8M against about $230.1M expected and non-GAAP EPS of $1.26 against $1.10. Management guided Q4 revenue to about $275M and non-GAAP EPS to about $1.50, both well above the estimates cited, and said bookings rose strongly. Gross margin was pressured by FX, with non-GAAP gross margin at 41.2%, down from 41.8% a year earlier. The stock nonetheless fell to a $90.00 close on Nov 5, on volume of about 1.04M shares versus roughly 300K–500K on typical days in late October, and then recovered to $106.79 by Nov 10, a rebound of about 19% from that low. The recovery was accompanied by sustained volume of 530K–860K shares a day. B. Riley kept its Buy rating but cut its target to $140 from $165, which still implies upside of roughly 31% from Nov 10's close. Offsetting risks include the Veeco merger, now expected to close only by end of Q1 2027 and still awaiting SAMR clearance and a new HSR filing, plus a CFO transition with Jeroen Delsman starting Nov 12. The news set does not explain the roughly 11% drop on Oct 30, so that move is not attributed to a cause here.
News behind the analysis
- Axcelis Technologies Announces Financial Results for Third Quarter 2026Q3 revenue of $237.8M, GAAP diluted EPS of $1.21 and non-GAAP EPS of $1.26, with CEO Russell Low citing strong bookings growth across end markets. Management expects further growth in 2027.
- Axcelis Technologies Sees Q4 Adj EPS $1.50 vs $1.22 Est; Sees Sales $275.000M vs $238.795M EstFourth-quarter guidance calls for revenue of about $275M and non-GAAP EPS of about $1.50, both above the consensus estimates cited by Benzinga.
- Axcelis Technologies Q3 Adj. EPS $1.26 Beats $1.10 Estimate, Sales $237.781M Beat $230.100M EstimateThird-quarter adjusted EPS and revenue both came in above analyst estimates.
- Axcelis Technologies Q3 2026 Earnings Call TranscriptTranscript of the Q3 2026 call, where management discussed the bookings increase and the recovery across memory, power and general mature end markets.
- B. Riley Adjusts Axcelis Technologies Price Target to $140B. Riley cut its price target to $140 from $165 but kept its Buy rating after the quarter.
- B. Riley Securities Reiterates Buy on Axcelis Technologies, Lowers Price Target to $140B. Riley reiterated its Buy rating on Axcelis and lowered its price target to $140.
- Axcelis Technologies and Veeco Instruments Provide Update on Expected Timing of Merger ClosingThe all-stock merger with Veeco is now expected to close by the end of Q1 2027, pending China's SAMR clearance and a new HSR Act filing. Each Veeco share converts into 0.3575 Axcelis shares.
About Axcelis Technologies Inc
Axcelis Technologies is a Beverly, Massachusetts maker of ion implantation equipment, the machines that put precise amounts of dopant atoms into silicon wafers during chip manufacturing. It focuses almost entirely on implant tools and is strongest in mature-node chips and silicon carbide power devices. It has a pending all-stock merger with Veeco Instruments (VECO), now expected to close by the end of Q1 2027 once China's regulator approves it.
How it makes money
Most revenue comes from selling its Purion ion implant systems to chipmakers. In the first half of 2026, about 77% of system shipments went to mature process chips (such as power, silicon carbide, image sensors and analog) and about 22% to DRAM memory. Its CS&I business (customer support and innovation: spare parts, service and upgrades for the many tools already in use) brings in a steadier, growing share of revenue and profit. Sales are concentrated: the ten largest customers made up roughly 70% of revenue in the first half of 2026.
What usually moves ACLS
- Chipmaker capital spending on mature-node fabs
- Silicon carbide and power-device demand (EVs, industrial)
- China customer demand and US export restrictions
- Memory (DRAM) investment cycles
- Progress on the Veeco merger and regulatory approvals